Filter
1137
Filtered Results: 1137
Text search:
antibodies
Featured
Recommendations
149
New Publications
286
Language
Document type
No document type
565
Guidelines
239
Studies & Reports
140
Manuals
60
Fact sheets
56
Strategic & Response Plan
27
Training Material
20
Situation Updates
10
Brochures
6
Resource Platforms
5
Infographics
4
Videos
4
App
1
Countries / Regions
India
93
Global
53
Nigeria
23
Nepal
22
Latin America and the Carribbean
21
South Africa
20
Tanzania
18
Philippines
16
Africa
15
Indonesia
14
Kenya
13
Middle East and North Africa
13
Western and Central Europe
13
Germany
12
Russia
12
Ethiopia
12
Liberia
12
Syria
11
Brazil
11
Sierra Leone
10
Malawi
10
West and Central Africa
10
East and Southern Africa
10
Uganda
10
Rwanda
9
Zambia
9
Congo, Democratic Republic of
7
Eastern Europe
7
Myanmar / Burma
7
Venezuela
6
Bangladesh
6
Namibia
6
Colombia
5
Ukraine
5
Yemen
5
Burkina Faso
4
Afghanistan
4
Peru
4
Guinea
4
South–East Asia Region
4
Pakistan
4
Lesotho
3
Turkey
3
Cameroon
3
Zimbabwe
3
Mozambique
3
USA
3
Cambodia
3
Asia
3
Saudi Arabia
3
Spain
3
Lebanon
3
Mali
3
South Sudan
3
Ecuador
3
Mexico
2
Ghana
2
Senegal
2
Niger
2
Qatar
2
Haiti
2
Jordan
2
Eastern Europe and Central Asia
2
Paraguay
2
North America
2
France
2
United Kingdom
2
Côte d’Ivoire / Ivory Coast
2
Bolivia
2
Argentina
2
Vietnam
2
Egypt
2
Sudan
2
Georgia
2
Chad
2
Libya
2
Botswana
2
Iraq
2
Somalia
2
Madagascar
2
Eswatini/ Swaziland
2
North Macedonia
1
Tajikistan
1
El Salvador
1
Serbia
1
Benin
1
Togo
1
China
1
Kazakhstan
1
Chile
1
Iran
1
Congo-Brazzaville
1
Uzbekistan
1
Morocco
1
Mauritania
1
Armenia
1
Dominican Republic
1
Western Pacific Region
1
Jamaica
1
Tunisia
1
Portugal
1
Belarus
1
Israel
1
Southern Africa
1
Papua New Guinea
1
Nicaragua
1
Moldova
1
Sri Lanka
1
Djibouti
1
Palestine
1
Poland
1
Honduras
1
Angola
1
Cuba
1
Guatemala
1
Authors & Publishers
Publication Years
Category
Countries
369
Clinical Guidelines
176
Public Health
48
Women & Child Health
44
Pharmacy & Technologies
41
Capacity Building
26
Key Resources
16
Toolboxes
COVID-19
215
HIV
119
NTDs
88
Rapid Response
70
Ebola
47
TB
35
Zika
35
Refugee
23
Mental Health
21
Pharmacy
20
NCDs
20
Caregiver
16
Planetary Health
13
Polio
13
AMR
12
Cholera
6
Natural Hazards
4
Conflict
4
Health Financing Toolbox
3
Specific Hazards
2
Disability
2
Global Health Education
2
Malgré les progrès récents vers la mise au point d’un traitement hautement efficace et abordable contre le virus de l’hépatite C, beaucoup de personnes infectées par ce virus ne connaissent pas leur statut. L’Organisation mondiale de la Santé (OMS) estime qu’en 2019, 58 millions ...
As a high-burden neglected tropical disease, soil-transmitted helminth (STH) infections remain a major problem in the world, especially among children under five years of age. Since young children are at high risk of being infected, STH infection can have a long-term negative impact on their life, i...
Following the publication of Guidelines on certification of elimination of human onchocerciasis in 2001 by the World Health Organization (WHO), these are the first evidence-based guidelines developed by NTD Department according to the international standards. They provide a set of recommendations th...
Organización Mundial de la Salud. (2022). Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022.
Due to high routine vaccination coverage, overall counts of diphtheria case have significantly declined in the Western Pacific Region recently. However, diphtheria is still prevalent in several countries and areas of the Region and remains a public health issue due to its high case fatality rate.
...
Diagnosis, Case Management Prevention and Control of Leptospirosis
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...
This document provides technical guidance on concepts, definitions, indicators, criteria, milestones and tools to assist leprosy programmes in their journey towards the goals of interruption of transmission and elimination of leprosy disease and through the post-elimination period. Importantly, it p...
Despite the development of point-of-care diagnostic tests for syphilis, chlamydia, gonorrhoea, and trichomoniasis, none comply with all WHO criteria. This analysis overviews landscape analyses of point-of-care diagnostic technologies for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vagi...
CEPI is seeking to raise $3.5 billion to implement CEPI’s next 5-year plan. To mitigate the immediate threat of COVID-19 variants, it is activating key elements of this plan now—and seeking to mobilise a portion of this $3.5 billion in 2021. We have already launched R&D programmes to initiate de...
Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected.
Infection prevention and control (IP...
The waves of yellow fever transmission in the Region of the Americas in 2016–2018 involved the largest number of human and epizootic cases to be reported in several decades. Yellow fever is a serious viral hemorrhagic disease that poses a challenge for health professionals. It requires early recog...
Cholera remains a significant public health threat in many countries worldwide. In resource-constrained settings, it disproportionately affects thousands of poor and vulnerable population
Case definitions, clinical classification, and disease phases Dengue, Chikungunya, and Zika
recommended
A person who lives in or has traveled in the previous 14 days to areas with dengue transmission, and presents with acute fever that has typically lasted 2 to 7 days, and two or more of the following clinical manifestations: nausea or vomiting, exanthema, headache or retro-orbital pain, myalgia or ar...
Access to safe blood and blood products is recognized as one of the key requirements for delivery of modern health care in the journey towards health for all. The foundation of safe and sustainable blood supplies depends on the collection of blood from voluntary non-remunerated and low-risk donors. ...
Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for...
This document lays out economic arguments for investing in the Access to COVID-19 Tools Accelerator (ACT-Accelerator). Framed within an overall context that recognizes the broader human health and societal impacts of the COVID-19 crisis, ACT-Accelerator's Economic Investment Case argues that investm...
Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipopr...
This publication aims to provide updated guidance on the specific use of yellow fever laboratory assays in the context of surveillance to be used across the Global Yellow Fever Laboratory Network for disease surveillance. In the recent years, new commercial assays became available and are now recomm...
